These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://kiaraqniw671381.xzblogs.com/79427101/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide